Hypersensitivity Pneumonitis
24
6
7
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
4.2%
1 terminated out of 24 trials
88.9%
+2.4% vs benchmark
13%
3 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (24)
A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis
"Randomized Controlled Trial Testing the Efficacy of Corticosteroid Therapy Versus Placebo in Fibrotic Hypersensitivity Pneumonitis"
Interstitial Lung Disease Research Unit Biobank
Prognostic Score Comparison in IPF and HP
FAPI PET for Lung Fibrosis
Reimagining Interventions for Support and Education in Hypersensitivity Pneumonitis
Skeletal Muscle Function in Interstitial Lung Disease
Stop Exogenous Allergic Alveolitis (EAA) in Childhood
Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases
University of Virginia Natural History Study
Database and Biobank of Patients With Hypersensitivity Pneumonitis
Contribution of the Indoor Environment Medical Advisor in the Management of Fibrosing Hypersensitivity Pneumonitis
Assessing Health Related Quality of Life in Hypersensitivity Pneumonitis
HypErsensitiVity PneumonITis: DiseAse Progression Characterization
Study of Nasal Mucosa Histopathological Changes in Chronic Hypersensitivity Pneumonitis
An RCT of Mycophenolate Mofetil (MMF) in Fibrotic Hypersensitivity Pneumonitis
129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study
Predictors of Pulmonary Hypertension in Patients With Hypersensitivity Pneumonitis
Immune Response in Hypersensitivity Pneumonitis
Evaluation of the Efficacy of Pirfenidone in Progressive Chronic Hypersensitivity Pneumonitis